Patients and methods When planning the study we estimated the SD of the mean lower leg growth rate to be 0-20 mm! week.36 On this assumption we calculated that 12 patients would be sufficient for a power of >0 90 to detect a 50% reduction in growth rate, which was considered a clinically relevant difference.9 As some withdrawals were to be expected the study population was increased by seven patients.
As inhaled glutocorticosteroids are becoming increasingly used for prophylaxis in childhood asthma, renewed attention is drawn to the risk of adverse systemic effects such as suppression of linear growth.' Knemometry has been established as an integral part ofthe available measures of systemic activity of topical steroids in children. 23 By measuring changes in lower leg length with an accuracy of 0 09-0-11 mm45 the knemometer provides a powerful tool for investigating the influence of exogeneous glucocorticosteroids on linear growth in children. 6 Fluticasone propionate is a potent topically active synthetic glucocorticosteroid currently in clinical development as an inhaled steroid preparation for the treatment of asthma.7 Beclomethasone dipropionate is an inhaled glucocorticosteroid widely used for many years. 8 The aim of this study was to compare short term linear growth measured by knemometry in children with mild asthma during treatment with these two inhaled glucocorticosteroids.
Patients and methods When planning the study we estimated the SD of the mean lower leg growth rate to be 0-20 mm! week.36 On this assumption we calculated that 12 patients would be sufficient for a power of >0 90 to detect a 50% reduction in growth rate, which was considered a clinically relevant difference. 9 As some withdrawals were to be expected the study population was increased by seven patients.
Nineteen children, outpatients in a secondary referral centre, entered the study. All had mild asthma requiring only treatment as needed with inhaled 132 stimulants. None had received treatment with glucocorticosteroids either inhaled or by mouth for two months before the study and no other drug was taken during the study period. Two girls and one boy were stage 2 according to Tanner's rating of puberty."' The other children were preadolescents without any signs of puberty. Table 1 gives the patient data. The study was approved by the local ethics committee and informed consent was obtained from all children and their parents.
The study design was a double blind, crossover trial with three active treatment periods and two wash out periods. After a run in period of four days (period 1) during which the children took no treatment except inhaled 12 agonists they were randomised to treatment with fluticasone propionate 200 rig/day and beclomethasone dipropionate 400 and 800 ,ug/day in periods 2, 4, and 6. Treatment order was allocated by a computerised randomisation scheme prepared in balanced blocks. In periods 3 and 5 (wash out periods) placebo was given. Periods 2-6 were each 15 days long. The drug was taken in the morning and in the evening as one blister from a dry powder Diskhaler (Glaxo). The Diskhalers, identical in size and appearance, were delivered in identical boxes labelled with case number, period number, and prescription. During the run in period a placebo Diskhaler was used by the children so that they would become used to inhaling from the device. The inhalation technique was checked at each visit. To ensure optimum compliance the number of consumed blisters was counted at every visit. gives a normal range for cranial surface umbilical skin length measured from the junction ofthe abdominal wall and umbilicus to the junction of umbilical skin and gelatinous cord with gentle traction on the cord. In 104 babies of between 36 and 43 weeks' gestation and 2235 to 5490 g birth weight this measurement was not dependant on sex, gestation, weight, or body length. It did, however, slowly decrease between birth and 48 hours of age after which it remained constant up to 90 hours. Mean cranial surface umbilical skin length (95% confidence intervals) at birth was mm (75 to 200) and at 48 hours 8-7 mm (25 to .
Why would you wish to measure umbilical skin length? It might help in the diagnosis of several dysmorphic syndromes especially Rieger's syndrome (autosomal dominant, goniodysgenesis, midface hypoplasia, variable hypodontia). Other syndromes with abnormal umbilical morphology include Aarskog's syndrome (X linked recessive, small stature, unusual facies, genital anomalies) and Robinow's syndrome (autosomal dominant, possibly recessive in some, 'fetal face', short forearms, genital hypoplasia, growth deficiency).
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